Cisplatin and infusional cytosine arabinoside for the treatment of colorectal adenocarcinoma: A phase II trial

Merry Tetef, Lucille Leong, Chul Ahn, Steven Akman, Warren Chow, Kim Margolin, Robert J. Morgan, James Raschko, Stephen Shibata, George Somlo, James H. Doroshow

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

Based on the in vitro and in vivo synergy between cytosine arabinoside (Ara-C) and cis-diamminedichloroplatinum (cisplatin), we designed a phase II trial of Ara-C with cisplatin for patients with colorectal adenocarcinoma. Forty-eight eligible patients received continuous infusion Ara-C, 30 mg/m2/day over 72 hr, plus cisplatin, 30 mg/m2 for three doses at hours 12, 36, and 60 of the Ara-C infusion. The objective partial response rate for patients with colon carcinoma was 3% (1/32 patients; 95% CI, 0-16%) with a median response duration of 2.8 months. None of the 16 patients treated for rectal carcinoma responded. Myelosuppression was the most severe toxicity. Significant gastrointestinal and hepatic toxicities occurred in a small number of patients. Nephrotoxicity and neurotoxicity were mild. We conclude that the prolonged infusion of Ara-C in combination with divided doses of cisplatin offers no significant therapeutic advantage.

Original languageEnglish (US)
Pages (from-to)114-117
Number of pages4
JournalCancer Investigation
Volume17
Issue number2
DOIs
StatePublished - Jan 1 1999

Keywords

  • Cisplatin
  • Colon carcinoma
  • Cytosine arabinoside
  • Phase II trial
  • Rectal carcinoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Cisplatin and infusional cytosine arabinoside for the treatment of colorectal adenocarcinoma: A phase II trial'. Together they form a unique fingerprint.

  • Cite this

    Tetef, M., Leong, L., Ahn, C., Akman, S., Chow, W., Margolin, K., Morgan, R. J., Raschko, J., Shibata, S., Somlo, G., & Doroshow, J. H. (1999). Cisplatin and infusional cytosine arabinoside for the treatment of colorectal adenocarcinoma: A phase II trial. Cancer Investigation, 17(2), 114-117. https://doi.org/10.1080/07357909909011725